EPCAM and neoplasm: EV-mediated reduction in drug availability has also been observed in epithelial cell adhesion molecule (EpCam)-positive breast cancer cells treated with the EpCam-specific antibody C215, suggesting a correlation between EV release and tumor progression [16].